Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

The targeted production of the dual vector Sputnik V for the fIrst 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production.

Sun Pharma has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company Lilly for expanding access to Lillys drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.

U.S. Food and Drug Administration, FDA, has expanded the Emergency Use Authorization, EUA, for Pfizer COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.

The Drugs Controller General of India, DCGI, has given permission for the emergency use of 2 deoxyD-glucose, 2-DG medicine as an adjunct therapy in moderate to severe Covid-19 cases.

An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

Institute of Life Sciences Bhubaneswar, an autonomous institute of the Department of Biotechnology, Ministry of Science & Technology, Government of India invites applications from Indian Nationals to join in the following positions coterminous with the project duration.

Project title : Anti-viral screening platform for viral diseases : with special reference to COVID-19.